Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients-Reference-Cited by-同舟云学术

Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients

Published:2015-06 Issue:6 Volume:37 Page:1317-1328.e2
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Barnes Rosemary,Earnshaw Stephanie,Herbrecht Raoul,Morrissey Orla,Slavin Monica,Bow Eric^ORCID,McDade Cheryl,Charbonneau Claudie,Weinstein David,Kantecki Michal,Schlamm Haran,Maertens Johan

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference27 articles.

1. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors;Marr;Blood,2002

2. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach;Ananda-Rajah;Antimicrob Agents Chemother,2011

3. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology;Cornely;Haematologica,2009

4. Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK;Ceesay;J Antimicrob Chemother,2015

5. Evaluation of treatment of invasive fungal infections;Casucci;J Pharmacol Pharmacother,2014

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of posaconazole prophylaxis and antifungal treatment on BAL GM performance in hematology malignancy patients with febrile neutropenia: a real life experience;European Journal of Clinical Microbiology & Infectious Diseases;2023-11-01

2. Overcoming clinical challenges in the management of invasive fungal infections in low- and middle-income countries (LMIC);Expert Review of Anti-infective Therapy;2023-09-24

3. Introducing biomarkers for invasive fungal disease in haemato-oncology patients: a single-centre experience;Journal of Medical Microbiology;2022-07-12

4. PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia;JAC-Antimicrobial Resistance;2022-07-04

5. Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom;Microbiology Spectrum;2022-06-29